Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Bell

Showing results (811-820 of 1,036) with videos related to

Pageof 104
Sort By:
Schizophrenia Bulletin|April 6, 2024
Adverse Events Reporting in Digital Interventions Evaluations for Psychosis: A Systematic Literature Search and Individual Level Content Analysis of Adverse Event ReportsStephanie Allan, Thomas Ward, Emily Eisner, et al.
Histopathology|February 15, 2000
Monoclonal antibodies recognizing CD5, CD10 and CD23 in formalin-fixed, paraffin-embedded tissue: production and assessment of their value in the diagnosis of small B-cell lymphomaP Watson, K M Wood, A Lodge, et al.
Diabetes, Obesity & Metabolism|March 30, 2007
beta-blocker use and diabetes symptom score: results from the GEMINI studyJ B McGill, G L Bakris, V Fonseca, et al.
Scandinavian Journal of Gastroenterology|January 23, 1998
Interferon-alpha 2b therapy in low-activity hepatitis C: a pilot studyI Nordøy, H B Krarup, H Bell, et al.
The American Journal of Medicine|July 3, 2007
Body weight changes with beta-blocker use: results from GEMINIFranz H Messerli, David S H Bell, Vivian Fonseca, et al.
Genome Medicine|April 26, 2017
PathOS: a decision support system for reporting high throughput sequencing of cancers in clinical diagnostic laboratoriesKenneth D Doig, Andrew Fellowes, Anthony H Bell, et al.
Radiation Oncology (London, England)|May 10, 2012
An athymic rat model of cutaneous radiation injury designed to study human tissue-based wound therapyLucas H Rifkin, Strahinja Stojadinovic, Collin H Stewart, et al.
Oncotarget|May 3, 2017
Metabolic heterogeneity signature of primary treatment-naïve prostate cancerDong Lin, Susan L Ettinger, Sifeng Qu, et al.
Oncotarget|March 26, 2016
The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cellsMark P Labrecque, Mandeep K Takhar, Rebecca Nason, et al.
Annals of Internal Medicine|December 3, 2002
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trialSusan L Greenspan, Ronald D Emkey, Henry G Bone, et al.
Pageof 104

Showing results (811-820 of 1,036) with videos related to

Sort By:
Pageof 104
Schizophrenia Bulletin|April 6, 2024
Adverse Events Reporting in Digital Interventions Evaluations for Psychosis: A Systematic Literature Search and Individual Level Content Analysis of Adverse Event ReportsStephanie Allan, Thomas Ward, Emily Eisner, et al.
Histopathology|February 15, 2000
Monoclonal antibodies recognizing CD5, CD10 and CD23 in formalin-fixed, paraffin-embedded tissue: production and assessment of their value in the diagnosis of small B-cell lymphomaP Watson, K M Wood, A Lodge, et al.
Diabetes, Obesity & Metabolism|March 30, 2007
beta-blocker use and diabetes symptom score: results from the GEMINI studyJ B McGill, G L Bakris, V Fonseca, et al.
Scandinavian Journal of Gastroenterology|January 23, 1998
Interferon-alpha 2b therapy in low-activity hepatitis C: a pilot studyI Nordøy, H B Krarup, H Bell, et al.
The American Journal of Medicine|July 3, 2007
Body weight changes with beta-blocker use: results from GEMINIFranz H Messerli, David S H Bell, Vivian Fonseca, et al.
Genome Medicine|April 26, 2017
PathOS: a decision support system for reporting high throughput sequencing of cancers in clinical diagnostic laboratoriesKenneth D Doig, Andrew Fellowes, Anthony H Bell, et al.
Radiation Oncology (London, England)|May 10, 2012
An athymic rat model of cutaneous radiation injury designed to study human tissue-based wound therapyLucas H Rifkin, Strahinja Stojadinovic, Collin H Stewart, et al.
Oncotarget|May 3, 2017
Metabolic heterogeneity signature of primary treatment-naïve prostate cancerDong Lin, Susan L Ettinger, Sifeng Qu, et al.
Oncotarget|March 26, 2016
The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cellsMark P Labrecque, Mandeep K Takhar, Rebecca Nason, et al.
Annals of Internal Medicine|December 3, 2002
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trialSusan L Greenspan, Ronald D Emkey, Henry G Bone, et al.
Pageof 104